Responses
Clinical/translational cancer immunotherapy
Original research
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.